[1] Han L, Fu L, Peng Y, et al. Triggering receptor expressed on myeloid cells-1 signaling: protective and pathogenic roles on streptococcal toxic-shock-like syndrome caused by streptococcus suis[J]. Front Immunol, 2018, 9: 577.
[2] Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes[J]. J Immunol, 2000, 164(10): 4991-4995.
[3] Wang X, Luo B, Lu Y, et al. The triggering receptor expressed by myeloid cells-1 activates TLR4-MyD88-NF-kappaB-dependent signaling to aggravate ventilation-induced lung inflammation and injury in mice[J]. Cell Tissue Res, 2018, 374(1): 137-148.
[4] Bouchon A, Facchetti F, Weigand MA, et al. TREM-1 amplifies inflammation and is a crucial mediator of septic shock[J]. Nature, 2001, 410(6832): 1103-1107.
[5] Liu T, Zhou Y, Li P, et al. Blocking triggering receptor expressed on myeloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation[J]. Sci Rep, 2016, 6: 39473.
[6] Croteau-Chonka DC, Raby BA. TREM-1 response signatures common to expression profiles of both asthma affection and asthma control[J]. Am J Respir Crit Care Med, 2018, 198(3): 401-404.
[7] 宋卓慧, 孙国瑛, 周勇, 等. 脂多糖对小鼠巨噬细胞TREM-1表达的影响[J]. 长治医学院学报, 2012, 26(2): 81-83.
[8] Fu L, Han L, Xie C, et al. Identification of extracellular actin as a ligand for triggering receptor expressed on myeloid cells-1 signaling[J]. Front Immunol, 2017, 8: 917.
[9] Zhu J, Duan G, Wang H, et al. TREM-1 activation modulates dsRNA induced antiviral immunity with specific enhancement of MAPK signaling and the RLRs and TLRs on macrophages[J]. Exp Cell Res, 2016, 345(1): 70-81.
[10]Ramhorst R, Calo G, Paparini D, et al. Control of the inflammatory response during pregnancy: potential role of VIP as a regulatory peptide[J]. Ann N Y Acad Sci, 2018. doi: 10.1111/nyas.13632.
[11]Verma AK, Manohar M, Upparahalli Venkateshaiah S, et al. Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases[J]. Cytokine Growth Factor Rev, 2017, 38: 37-48.
[12]Sun GY, Yang HH, Guan XX, et al. Vasoactive intestinal peptide overexpression mediated by lentivirus attenuates lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammation[J]. Mol Immunol, 2018, 97: 8-15.
[13]Sun GY, Guan CX, Zhou Y, et al. Vasoactive intestinal peptide re-balances TREM-1/TREM-2 ratio in acute lung injury[J]. Regul Pept, 2011, 167(1): 56-64.
[14]宋卓慧. 血管活性肠肽对急性肺损伤时肺内TREM-1表达的影响及其机制[D]. 中南大学, 2012.
[15]骆凤, 郑浩翔, 董良, 等. 地塞米松对急性肺损伤中TREM-1表达的影响[J]. 中国临床解剖学杂志, 2016, 34(5): 523-527.
[16]Solanki A, Bhatt LK, Johnston TP. Evolving targets for the treatment of atherosclerosis[J]. Pharmacol Ther, 2018, 187: 1-12.
[17]Tammaro A, Derive M, Gibot S, et al. TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives[J]. Pharmacol Ther, 2017, 177: 81-95.
[18]Ran WZ, Dong L, Tang CY, et al. Vasoactive intestinal peptide suppresses macrophage-mediated inflammation by downregulating interleukin-17A expression via PKA- and PKC-dependent pathways[J]. Int J Exp Pathol, 2015, 96(4): 269-275.
[19]Juarranz MG, Santiago B, Torroba M, et al. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells[J]. Rheumatology (Oxford), 2004, 43(4): 416-422.
[20]Calo G, Sabbione F, Vota D, et al. Trophoblast cells inhibit neutrophil extracellular trap formation and enhance apoptosis through vasoactive intestinal peptide-mediated pathways[J]. Hum Reprod, 2017, 32(1): 55-64.
[21]Zhao SJ, Wang DH, Li YW, et al. A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects[J]. Int J Nanomedicine, 2017, 12: 2143-2160.
[22]Athari SS, Pourpak Z, Folkerts G, et al. Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice[J]. Eur J Pharmacol, 2016, 791: 811-820. |